Loading video.
VIDEO: UC San Diego students can participate in a nationwide clinical trial to assess how well a COVID-19 vaccine prevents infection and reduces risk of transmission. Watch this video to learn. view more
Credit: UC San Diego Health Sciences
COVID-19 vaccines were designed to reduce the likelihood that infection by the SARS-CoV-2 virus would lead to severe outcomes, such as hospitalization and death. In that sense, all of the currently approved vaccines Moderna, Pfizer and Johnson & Johnson have proven comparably effective.
But much less is known about the actual ability of these vaccines to prevent infection, most notably asymptomatic cases in which vaccinated persons might not become ill or display symptoms, but could still carry sufficient levels of the virus to pose a potential transmission threat to others.
Study on how successful are COVID-19 vaccines over time
news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
New scholarship could open more doors for most promising medical students
news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Inozyme Pharma Expands its Scientific Advisory Board
Inozyme Pharma Inc.April 1, 2021 GMT
BOSTON, April 01, 2021 (GLOBE NEWSWIRE) Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of disorders of abnormal mineralization, announced today changes to its scientific advisory board (SAB), including the addition of three leading key opinion leaders with specific expertise in the company’s lead indications:
W Charles O’Neill IV, M.D., Director of the Ultrasonography Program in the Renal Division at Emory University School of Medicine
Novel Drug Prevents Amyloid Plaques, a Hallmark of Alzheimer’s Disease In animal models, the new compound modulated a key enzyme, reducing or eliminating production of problematic protein fragments; human clinical trials needed March 02, 2021 | Scott LaFee
News release
Amyloid plaques are pathological hallmarks of Alzheimer’s disease (AD) clumps of misfolded proteins that accumulate in the brain, disrupting and killing neurons and resulting in the progressive cognitive impairment that is characteristic of the widespread neurological disorder.
In a new study, published March 2, 2021 in the
Journal of Experimental Medicine (JEM), researchers at University of California San Diego School of Medicine, Massachusetts General Hospital and elsewhere have identified a new drug that could prevent AD by modulating, rather than inhibiting, a key enzyme involved in forming amyloid plaques.